Manhattan Scientifics Announces the Engagement of Loraine Upham to Market Its Cancer Diagnostic Technology
August 23 2013 - 9:00AM
Business Wire
Manhattan Scientifics (OTCQB:MHTX) announced
today that Loraine Upham has been engaged as a consultant to
support its cancer team. The technology, developed by Edward R.
Flynn, PhD, provides the most specific and most sensitive method
for detecting cancer currently known. Ms. Upham’s role will be to
identify initial markets and facilitate relationships with
strategic partners for the company.
Loraine Upham has over 30 years of biotechnology
commercialization experience. She is best known for her
co-invention and development of a novel treatment for diabetes that
was partnered in a $335M deal with Sanofi-Aventis in 2010.
Ms. Upham said, “It is an honor to work with Dr. Flynn and the
Senior Scientific team led by its president Gerald Grafe. This
company has terrific potential to impact markets in a number of
sectors through strategic partnerships. The technology is
extraordinary and can be applied to everything from drug discovery
and development and in vitro diagnostics to in vivo animal imaging
and quantification, while human clinical applications are
established.”
Senior Scientific, a unit of Manhattan Scientifics Inc., is
pioneering the technology, driving it from “bench to bedside”. The
technology uses non-toxic iron oxide nanoparticles and
ultrasensitive magnetic detection for a highly sensitive and very
specific approach to cancer detection that can locate and measure
tumors one millionth the size detectable by X-Rays and MRI.
Marvin Maslow, Manhattan Scientifics' founder said, "We are
involved in early collaborative planning with the U.S.'s No. 1
cancer research hospital because of our company’s ability to find
cancers years before other known methods.”
About Manhattan Scientifics
Manhattan Scientifics Inc. (www.mhtx.com) is located in New
Mexico, New York and Montreal. It is focused on technology transfer
and commercialization of transformative technologies in the nano
medicine space. The company is presently developing commercial
medical prosthetics applications for its ultra-fine grain metals
and plans to commercialize the cancer research work and nano
medical applications developed by Senior Scientific LLC, a unit of
the Company.
Forward-looking statement
This press release contains forward-looking statements, which
are subject to a number of risks, assumptions and uncertainties
that could cause the Company's actual results to differ materially
from those projected in such forward-looking statements. Management
at Manhattan Scientifics believes that purchase of its shares
should be considered to be at the high end of the risk spectrum.
Forward-looking statements speak only as of the date made and are
not guarantees of future performance. We undertake no obligation to
publicly update or revise any forward-looking statements.
Manhattan Scientifics (PK) (USOTC:MHTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Manhattan Scientifics (PK) (USOTC:MHTX)
Historical Stock Chart
From Apr 2023 to Apr 2024
